Effect of mesalazine combined with bifidobacteria in the treatment of ulcerative colitis

Objective To explore the clinical effect of mesalazine combined with bifidobacteria in the treatment of ulcerative colitis (UC). Methods The clinical data of 72 patients with UC were retrospectively analyzed.The patients were divided into the observation group (n=36) and control group (n=36) according to different treatment.The control group was given mesalazine, the observation group received mesalazine combined with bifidobacteria.The serum levels of superoxide dismutase (SOD), malondialdehyde (MDA) and C-reactive protein (CRP) were detected.The improvement of symptoms, clinical efficacy and adverse reactions were observed. Results Before treatment, the levels of MDA, SOD, CRP and the incidence of abdominal pain, diarrhea, mucus and blood stool between the two groups had no statistically significant differences.After treatment, the levels of MDA, SOD and CRP in the observation group were (6.01±0.58)nmol/mL, (1.53±0.56)U/mL, (5.07±0.98)mg/L, respectively, which in the control group were (6.53±0.66)nmol/mL, (1.53±0.56)U/mL, (6.03±2.54)mg/L, respectively, there were statistically significant differences between the two groups (t=4.550, 8.054, 5.115, all P<0.05). The incidence rates of diarrhea, abdominal pain, bloody mucus in the observation group were 0.00%, 2.78%, 2.78%, respectively, which in the control group were 11.11%, 16.67% and 16.67%, respectively, there were statistically significant differences between the two groups (χ2=6.235, 6.956, 7.956, all P<0.05). Conclusion Mesalazine combined with bifidobacteria in the treatment of UC can obviously reduce MDA, CRP levels, increase SOD activity, improve clinical symptoms, and its effect is better than mesalazine alone. Key words: Bifidobacterium; Colitis, ulcerative; Superoxide dismutase; Malondialdehyde